Host and Bacterial Factors Affecting Induction of Immune Responses to Flagellin Expressed by Attenuated *Salmonella* Vaccine Strains

M. E. Sbrogio-Almeida, T. Mosca, L. M. Massis, I. A. Abrahamsohn, and L. C. S. Ferreira*

Division of Technological Development and Production, Butantan Institute, and Department of Microbiology and Department of Immunology, Institute of Biomedical Sciences, São Paulo University, São Paulo, Brazil

Received 24 April 2003/Returned for modification 3 September 2003/Accepted 4 February 2004

Previous observations demonstrated that the delivery of recombinant *Salmonella enterica* serovar Dublin strains to mice via mucosal routes did not efficiently activate systemic and secreted antibody responses to either type *d* flagellin or genetically fused heterologous B-cell epitopes, thus reducing the usefulness of the protein as a carrier of epitopes for vaccine purposes. In this work, we investigated murine systemic and mucosal flagellin immunogenicity after oral immunization with attenuated *Salmonella* strains. The reduced anti-type *d* flagellin antibody responses in mice immunized via mucosal routes with three doses of flagellated *S. enterica* serovar Dublin strains were not caused by oral tolerance and could not be restored by coadministration of a mucosal adjuvant. The induction of antibody responses to *Salmonella* flagellins was shown to differ according to the genetic background, but not the haplotype, of the mouse lineage. Moreover, BALB/c mice orally immunized with *S. enterica* serovar Typhimurium strains developed anti-type *i* flagellin sera and secreted antibody responses, which indicated that the serovar of the *Salmonella* vaccine strain also affected flagellin immunogenicity. Analyses of cytokine responses of BALB/c mice immunized with three oral doses of flagellated *S. enterica* serovar Dublin vaccine strains showed that, in spite of the lack of antibody responses, elevated type *d* flagellin-specific CD4-cell-activation-dependent gamma interferon (IFN-γ) and interleukin-10 responses were elicited after the administration of the vaccine strains via either parenteral or mucosal routes. Similar cytokine production patterns were detected to a T-cell heterologous epitope, derived from the CFA/I fimbriae of enterotoxigenic *Escherichia coli* (ETEC), in mice orally immunized with a *Salmonella* vaccine strain expressing hybrid flagella. These results indicate that the immunogenicities of *Salmonella* flagellins can differ significantly, depending on the murine host and on the bacterial vector used, and demonstrate that the induction of CD4-cell-activation-dependent IFN-γ production represents a major immune response triggered by flagellin and in-frame fused heterologous T-cell epitopes after the oral administration of recombinant *S. enterica* serovar Dublin vaccine strains.

The *Salmonella*-flagellin system has been designed to activate immune responses to heterologous linear epitopes genetically fused to flagellin, the structural subunit of the flagellar filament, expressed by live *Salmonella enterica* serovar Dublin vaccine strains (31). The vaccine strategy was based on the cloning of the *S. enterica* serovar Muenchen *fliC* gene, which belongs to the same serological type (*d*) of the human pathogen *S. enterica* serovar Typhi, followed by the removal of an internal 48-bp EcoRV-EcoRV fragment located in hypervariable region IV which spans 350 bp at the central region of the gene (31, 39). The resulting plasmid, pLS408, allowed the in-frame fusion of heterologous sequences encoding up to 45 amino acids, in most cases without abolishing the motility function of the recombinant flagella (31–33, 39). The introduction of pLS408 into a nonflagellated attenuated *aroA S. enterica* serovar Dublin strain, SL5928, able to express a somatic antigen (*O* antigen) similar to that found in *S. enterica* serovar Typhi, represented a further step toward the development of live bivalent *Salmonella* vaccine strains that are suitable for human use (31, 39).

The first peptide to be expressed as a genetic fusion with *Salmonella* flagellin was a B-cell epitope derived from the cholera toxin B subunit (31). After that, several other B-cell epitopes, such as those derived from the hepatitis B virus surface protein, the *Streptococcus pyogenes* type 5 M protein, the human immunodeficiency virus gp160 surface protein, the structural subunit of the enterotoxigenic *Escherichia coli* (ETEC) colonization factor antigen I (*CFA/I*) fimbriae, influenza virus hemagglutinin, the surface antigen of *Schistosoma mansoni*, the class I outer membrane protein of *Neisseria meningitidis*, the VP7 protein of rotavirus, and the Plasmodium CS protein, among others, were expressed as fusions with the type *d* *Salmonella* flagellin (2, 3, 5, 26–28, 32, 33, 45). Most of the live vaccines were able to elicit specific serum antibody responses after parenteral immunization of mice. Nonetheless, attempts to immunize mice with the same strains via mucosal routes were frustrated by the reduced systemic and secreted antibody responses to flagellin-fused heterologous epitopes (5, 26, 27, 32, 39).

Recently we showed that the low-level antibody responses to peptides genetically fused to flagellin might be attributed, in contrast to the case for mice immunized via parenteral routes, to the reduced flagellin immunogenicity after delivery via mucosal routes (10, 36). The contrasting immunological behaviors of flagellin expressed by *Salmonella* vaccine strains delivered via different immunization routes did not reflect reduced gene expression or deficient host colonization-invasion by the bacterial vaccine strains (36). The elucidation of host and bacterial
fectors affecting the systemic and secreted immunogenicity of *Salmonella* flagellin still needs to be done, therefore, as an important step toward the more rational use of flagellin as a carrier of epitopes in vaccine formulations.

In the last few years, bacterial flagellin has been shown to possess strong immunostimulatory properties. Indeed, *Salmonella* flagellin is a potent inducer of proinflammatory mediators, such as NO, interleukin-1β (IL-1β), IL-8, IL-6, and tumor necrosis factor alpha, both in vitro and in vivo, in either rodents or humans (6–8, 12, 13, 24, 41, 46). Flagellin also represents a major antigen for activated CD4+ T cells in mice after oral infections with attenuated *S. enterica* serovar Typhimurium *aroA* strains, leading to CD4+-dependent gamma interferon (IFN-γ) production, a step required for the mounting of protective immunity against a challenge with virulent *Salmonella* strains (9, 29).

For this work, we investigated the immunogenicity of *Salmonella* flagellin following the administration of attenuated bacterial strains via mucosal or parenteral routes to mice of different lineages. The present observations show that the ability to mount systemic and secreted antibody responses to flagellin after oral immunization with *Salmonella* vaccine strains is affected by several factors concerning the genetic background of both the mammalian host and the bacterial vector. Moreover, we demonstrate that the type d *Salmonella* flagellin, as well as a genetically fused heterologous T-cell epitope, can elicit strong CD4+cell-activation-dependent IFN-γ and IL-10 production, irrespective of the administration route, in mice immunized with a live *S. enterica* serovar Dublin strain, which suggests that T-cell-dependent responses constitute a major aspect of the anti-flagellin responses elicited in mice orally immunized with *Salmonella* vaccine strains. Such an observation should contribute to a better use of the *Salmonella*-flagellin expression system as a bivalent mucosal vaccine approach and to a more detailed knowledge of *Salmonella*-induce immune responses in mouse models.

**MATERIALS AND METHODS**

**Bacterial strains and growth conditions.** *S. enterica* serovar Dublin SL5928 is a nonflagellated derivative of the *S. enterica* serovar Dublin *aroA* LS1438 strain, while the SL5930 strain is SL5928 transformed with pLS408, which promotes the expression of a type d flagellin encoded from an *S. enterica* serovar Muenchen *fliC* gene carrying a 48-bp deletion at the central hypervariable region of the gene (31). *S. enterica* serovar Dublin strain ICB5 is a flagellated derivative of the *aroA* SL7379 strain carrying a single copy of the deleted version of the *fliC* (d) gene integrated into the chromosome (36). *S. enterica* serovar Dublin strain FLAI1 is a derivative of the SL5928 strain transformed with plasmid pLG302, which encodes a hybrid flagellin genetically fused to a 15-amino-acid peptide, representing the major T-cell epitope of the structural subunit (ClAb) of the CFA/I fimbrae produced by some ETEC strains (26, 27). *S. enterica* serovar Typhimurium strain SL3261, a flagellated *aroA* strain, was kindly supplied by B. Stocker. *S. enterica* serovar Typhimurium strain LM408 was generated after the electroporation of pLS408 into strain LS3261. ETEC strain 258009-3 (CFA/I, O128:H7, ST:LT) and the corresponding isogenic CFAI-negative strain, 258009-3 M, were kindly offered by A. M. Svennerholm (Göteborg University, Göteborg, Sweden). All *Salmonella* strains were grown in Luria-Bertani (LB) broth at 37°C with aeration. Cultures of strains harboring pLS408 or pLG302 were supplemented with ampicillin (100 μg/ml). The ETEC strains were cultivated on CFA agar plates (25). All strains were stored at −70°C in LB medium containing 20% glycerol. Bacteria used as stimulants in cell cultures were inactivated by suspension in 70% ethanol and were kept overnight at 4°C before being added to cell cultures, at which time the suspensions were washed three times with excess sterile 0.01 M phosphate-buffered saline (PBS) in order to remove the ethanol.

**Mice and immunization protocols.** Specific-pathogen-free isogenic female mice of 8 to 12 weeks old from lineages BALB/c (H2d), C57BL/6 (H2b), B10.A (H2b), DBA/2 (H2d), A/J (H2b), B6.CBAJ (H2d), and C3H/HePas (H2s) were supplied by the Isogenic Mouse Breeding Facility of the Department of Immunology, Institute of Biomedicines, São Paulo State University, and São Paulo Research Foundation (FAPESP). Swiss albino mice, genetically selected (selection III) from outbred populations for high and low levels of antibody responsiveness to *Salmonella* antigens, were described previously (4, 37) and were kindly supplied by O. Ibanez from the Laboratory of Immunogenetics at the Butantan Institute (São Paulo, Brazil). All procedures were done in accordance with the principles of the Brazilian code for the use of laboratory animals and were approved by the Laboratory of Laboratory Animals from the Institute of Biomedical Sciences, USP. All immunizations were carried out using viable bacterial strains harvested during the exponential growth phase (optical density at 600 nm of 0.8). Bacteria were washed once by centrifugation with PBS and were suspended in sterile saline solution, for intraperitoneal (i.p.) and intranasal (i.n.) inoculations, or in 0.1 M sodium bicarbonate, for intragastric (p.o.) inoculations, to final concentrations ranging from 5 × 108 CFU ml−1 to 2 × 1010 CFU ml−1. Mice were inoculated p.o. with 0.5-ml aliquots of bacterial suspensions containing approximately 1010 CFU by use of a stainless steel round-tip gavage cannula on days 0, 21, and 35. The same immunization schedule was followed for the i.p. immunizations, but the bacterial loads were reduced to 109 CFU per dose. When performed, i.n. immunizations were performed in mice under light anesthesia, with 20 μl of bacterial suspension containing 107 CFU applied into the nostrils with the aid of a micropipette on days 0, 21, and 35. Blood collected from the retro-orbital plexus, feces, and lung washes were harvested 1 week after the last immunization dose. Fecal homogenates and lung washes were prepared as previously described (36). Serum, fecal, and lung wash samples were collected individually, but samples belonging to the same immunization groups (with 5 to 10 individuals) were pooled before the determination of antibody titers. All harvested biological samples were stored at −20°C until testing.

**Detection of *Salmonella* in mouse tissues.** Groups of three female BALB/c or C3H/HePas mice, with ages ranging from 8 to 12 weeks, were inoculated p.o. with a single dose of 1010 CFU of *S. enterica* serovar Dublin (strains ICB5 and SL5930) or *S. enterica* serovar Typhimurium (strains LM408 and SL3261). The animals were sacrificed 7 days after the inoculation and the small intestines and spleens were removed under aseptic conditions. Five Peyer’s patches (PP) and the whole spleen from each mouse were homogenized and serially diluted in PBS. Aliquots were plated on novobiocin-Luria plates and bacterial colonies were counted after 24 h of incubation at 37°C. pLS408 stability in the different bacterial hosts was evaluated after the inoculation of bacterial colonies onto L agar plates with or without added ampicillin (100 μg/ml). Flagellin expression in strain ICB5 was monitored by Western blotting of isolated bacterial colonies, using anti-flagellin H1-d serum raised in rabbits and peroxidase-conjugated anti-rabbit immunoglobulin G (IgG) antibodies, as previously described (36).

**Detection of oral tolerance and LT519202 adjuvant effects.** The induction of immunological tolerance to Salmonella flagellin was monitored in groups of 5 to 10 animals of BALB/c mice orally immunized with three doses (1010 CFU) of *S. enterica* serovar Dublin ICB5 on days 0, 21, and 35. Two weeks later, mice were injected i.p. with 10 μg of purified flagellin combined with 1 mg of aluminum hydroxide or with 109 CFU of the *Salmonella* ICB5 strain, and this was repeated once after 2 weeks. Serum (IgG) and mucosal (IgA) anti-flagellin antibody levels were measured 1 week after the last i.p. boost. Control groups included p.o. immunized animals receiving three doses of live *Salmonella* and animals that had been immunized i.p. with two doses of purified flagellin or *Salmonella* cells. The nontoxic derivative of the ETEC heat-labile toxin, LT519202, was obtained by site-specific mutagenesis (11) and was kindly supplied by J. Clements (Tulane University). BALB/c mice were immunized with *Salmonella* cell suspensions containing 25 or 1 μg of LT519202 for p.o. or i.n. immunizations, respectively. Sera, fecal extracts, and lung washes were collected 1 week after the last immunization and stored at −20°C until they were tested by enzyme-linked immunosorbent assay (ELISA) for anti-flagellin and anti-LT antibody responses.

**Detection of antibody responses.** All reagents and antisera for ELISAs were obtained from Sigma. Microtiter plates (Nalge Nunc, Roskilde, Denmark) were coated with purified *Salmonella* flagellins (0.1 μg/well) and *Salmonella* group D or group B lipopolysaccharide (LPS) (100 ng/well) in 0.05 M sodium bicarbonate buffer at pH 9.6 and were incubated overnight at 4°C. The plates were blocked with 1% gelatin in PBS for 1 h at 37°C, and serum, fecal extract, and lung wash pools, previously diluted in PBS with 0.05% Tween 20 (PBST), were added to the plates in series of twofold dilutions, followed by incubation for a further 2 h at 37°C. The plates were washed twice with PBST and reacted with mouse-specific IgG or IgA isotypes. After being washed with PBST, plates were developed with 0-phenylenediamine dihydrochloride, with H2O2 as a substrate.
Reactions were stopped with H₂SO₄ and absorbance values were measured at 492 nm in a microtiter plate spectrophotometer (Multiscan MS; LabSystem).

Endpoint titers were automatically calculated with the Microlab Origin 6.0 Professional program as the reciprocal values of the last dilutions with an optical density of 0.1. Results are expressed as arithmetic means ± standard errors of the means (SEM) of the endpoint titers of at least duplicate determinations.

**Purification of Salmonella flagellin and ETEC CFA/I fimbriae.** *Salmonella* flagellins expressed by *S. enterica* serovar Dublin ICB5 (type *d* flagellin) and *S. enterica* serovar Typhimurium SL3261 (type *f* and FljB flagellins) were purified by mechanical shearing and/or the acid monomerization procedure (23, 38). The CFA/I fimbriae were harvested from ETEC cells grown on CFA plates and were purified by ammonium sulfate precipitation, followed by DEAE-cellulose chromatography, performed according to previously described procedures (14).

**T-cell assays.** Splenocytes from immunized BALB/c mice were removed and single-cell suspensions were prepared in RPMI 1640 medium supplemented with 5% fetal calf serum, 2 mM l-glutamine, 0.05% 2-mercaptoethanol, penicillin (100 U/ml), and streptomycin (100 µg/ml) as previously described (16). Spleen cells were distributed (5 × 10⁶/well) in 24-well cell culture plates (Costar, Cambridge, Mass.) and cultured at 37°C in a 5% CO₂ enriched atmosphere in duplicate for 24 h (for IL-2 or IL-4 determinations) or 72 h (for IFN-γ or IL-10 determinations) in the presence of purified *Salmonella* type *d* flagellin (25 µg/ml), ethanol-inactivated Salmonella or ETEC cells (10⁷ bacteria/well), or purified CFA/I fimbriae (25 µg/ml). For some experiments, polymyxin B (40 µg/ml), an inhibitor of LPS activity, was added to the cultures together with the purified flagellin preparations in order to demonstrate the lack of LPS contamination. At the end of the incubation periods, the supernatants were removed and stored at −20°C for the determination of cytokine levels by ELISA.

**Cytokine ELISAs.** The IFN-γ, IL-10, IL-2, and IL-4 levels were determined by using two-site sandwich ELISAs with duplicate splenocyte culture supernatants as previously described (1). Detection limits for the cytokine ELISAs were 0.78 ng/ml for IFN-γ, 3.125 U/ml for IL-10, 0.156 ng/ml for IL-4, and 0.391 ng/ml for IL-2. The results from representative experiments are expressed as the arithmetic means of determinations from duplicate cultures ± SEM. Each experiment was performed independently at least three times.

**T-cell population involved in cytokine responses elicited by flagellin.** The identification of CD4+ or CD8+ cell-activation-dependent IFN-γ and IL-10 production in spleen cell cultures from mice immunized with flagellated *Salmonella* strains was done with specific neutralizing monoclonal antibodies (MAbs) to mouse CD4 (MAb GK 1-5, isotype IgG2b) or CD8 (MAb TIB105, isotype IgG2a). Anti-CD4 and anti-CD8 MAbs, as well as a control anti-β-galactosidase MAB (GL 117, isotype IgG2a), were used at a final concentration of 20 µg/ml. Splenocyte cultures were prepared in RPMI medium, as described above, added to the MAbs, and incubated for a further 24 h (for IL-2 and IL-4) or 72 h (for IFN-γ and IL-10). Culture supernatants were harvested by centrifugation and kept frozen at −20°C until the determination of their cytokine contents.

**Statistical analyses.** Results were analyzed by Student's *t* test. Statistical significance was defined as occurring when *P* values were <0.05.

**RESULTS**

Immunization with attenuated *S. enterica* serovar Dublin strains did not induce oral tolerance to flagellin. In contrast to the case for parenterally immunized mice, the administration of attenuated *aroA S. enterica* serovar Dublin strains to BALB/c or C57BL/6 mice via mucosal routes did not elicit significant serum (IgG) or secreted (IgA) antibody responses to type *d* flagellin, even with the stabilization of flagellin expression following integration of the *flhC* gene into the chromosome of the vaccine strain (36). One possible explanation for the reduced antiflagellin antibody responses elicited in mice immunized via mucosal routes with attenuated *Salmonella* strains could be the induction of an unresponsive immunological state, or tolerance, to specific bacterial antigens such as flagellin. To evaluate whether oral tolerance was the cause of the apparent low level of immunogenicity of *Salmonella* flagellin after delivery via mucosal routes, we first immunized BALB/c mice p.o. with three doses of the flagellated *S. enterica* serovar Dublin ICB5 strain and then immunized them i.p. with purified flagellin or live ICB5 cells. As shown in Fig. 1, control groups of mice that were only immunized i.p. with purified flagellin or live bacteria developed elevated systemic antiflagellin IgG titers (Fig. 1A, group 2), whereas mice that were only immunized p.o. with live *Salmonella* failed to develop serum antiflagellin IgG responses (Fig. 1, group 1). In a third group, mice that were previously immunized p.o. with the ICB5 strain generated robust anti-type *d* flagellin-specific IgG responses in serum after parenteral immunization with purified flagellin or with the ICB5 strain (Fig. 1, group 3). Similar results were obtained for the antiflagellin IgA responses in fecal extracts collected from the same mouse groups (data not shown), thus...
TABLE 1. Adjuvant effects of LT\textsubscript{R192G} on the serum anti-flagellin IgG and secreted IgA responses in BALB/c mice immunized with attenuated \textit{S. enterica} serovar Dublin ICB5 delivered via different routes

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Immunization route\textsuperscript{a}</th>
<th>Antibody titer\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Serum IgG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FLA</td>
</tr>
<tr>
<td>ICB5</td>
<td>i.p.</td>
<td>32,180 ± 2,574</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>50 ± 6</td>
</tr>
<tr>
<td></td>
<td>Nasal</td>
<td>16 ± 2</td>
</tr>
<tr>
<td>ICB5 plus LT</td>
<td>Oral</td>
<td>51 ± 4</td>
</tr>
<tr>
<td></td>
<td>Nasal</td>
<td>10 ± 2</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Immunizations were carried out with three doses of 10\textsuperscript{10} CFU (p.o.) or 10\textsuperscript{7} CFU (i.n. or i.p.) on days 0, 21, and 35. Serum, fecal, and lung wash samples were collected 1 week after the last immunization dose.

\textsuperscript{b} Titers were determined in ELISA plates treated with type \textit{d} flagellin (FLA) or purified LT\textsubscript{R192G} (LT). Values are means of endpoint titers ± SEM of serum pools prepared from each mouse group. Data are based on two independent experiments. ND, not done.

indicating that immunological tolerance does not contribute to the reduced immunogenicity of type \textit{d} \textit{Salmonella} flagellin as observed in mice immunized via the p.o. route with flagellated \textit{S. enterica} serovar Dublin vaccine strains.

Coadministration of a mucosal adjuvant (LT\textsubscript{R192G}) did not increase flagellin immunogenicity expressed by orally delivered \textit{S. enterica} serovar Dublin strains. LT and cholera toxin are the most potent and deeply studied mucosal adjuvants described thus far (44). LT enhances secreted and systemic antibody responses to coadministered soluble or particulate antigens, such as live \textit{Salmonella} cells, delivered via the oral route (19). In an attempt to enhance flagellin immunogenicity relative to its ability to induce secreted and systemic antibody responses, we orally or nasally immunized BALB/c mice with three doses of live ICB5 strain coadministered with LT\textsubscript{R192G} \textsuperscript{a} nontoxic LT derivative with preserved immunomodulatory properties (11). None of the mouse groups that were coimmunized with LT\textsubscript{R102G} and strain ICB5 showed a significant enhancement of antiflagellin IgG in serum or of fecal or lung wash IgA responses (Table 1). The detection of high levels of serum LT-specific IgG and IgA in samples collected from the same mouse groups confirmed that the immunizations were correctly performed. These results suggest that, unlike the case for other antigens, the reduced immunogenicity of type \textit{d} flagellin expressed by flagellated \textit{S. enterica} serovar Dublin strains delivered via the oral route cannot be efficiently rescued by the incorporation of a mucosal adjuvant.

Role of mammalian host and \textit{Salmonella} strain on flagellin immunogenicity. For an evaluation of the contribution of the genetic background of the murine host to the immunogenicity of \textit{Salmonella} flagellin, mice belonging to seven isogenic strains, expressing different haplotypes (B10A [H2\textsuperscript{a}], A/J [H2\textsuperscript{b}], CL57BL/6 [H2\textsuperscript{c}], BALB/c [H2\textsuperscript{d}], DBA/2 [H2\textsuperscript{e}], CBA/J [H2\textsuperscript{f}], and C3H/HePas [H2\textsuperscript{k}]) and carrying \textit{Ity} (Nramp) alleles conferring susceptibility or resistance to \textit{Salmonella} infection, were immunized with three doses of live \textit{S. enterica} serovar Dublin ICB5 via the i.p. or p.o. route. Upon parenteral immunization with the ICB5 strain, flagellin was shown to be a strong immunogen to all tested mouse lineages, as measured by the specific IgG responses in sera, with reverse titers ranging from 2 × 10\textsuperscript{5} (A/J) to 2.5 × 10\textsuperscript{4} (C57BL/6) (Table 2). On the other hand, one priming dose followed by two oral boosting doses with the same \textit{Salmonella} strain gave variable results. Most of the tested mouse strains expressed reduced or no systemic IgG responses to flagellin, but C3H/HePas mice developed significant antiflagellin serum IgG responses (reverse titer of 2,312 ± 221) (Table 2). Similar results were also found for the secreted antiflagellin IgA responses in feces of mice.

TABLE 2. Genetic backgrounds of different mouse strains affect the serum (IgG) responses to flagellin and LPS after immunization with attenuated \textit{S. enterica} serovar Dublin ICB5 delivered by the oral or i.p. route

<table>
<thead>
<tr>
<th>Mouse strain</th>
<th>\textit{Ity} allele\textsuperscript{a}</th>
<th>Haplotype</th>
<th>IgG antibody titer in serum\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Oral route</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LPS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LPS</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>S</td>
<td>H2\textsuperscript{k}</td>
<td>10,376 ± 1,350</td>
</tr>
<tr>
<td>BALB/c</td>
<td>S</td>
<td>H2\textsuperscript{a}</td>
<td>5,155 ± 495</td>
</tr>
<tr>
<td>B10A</td>
<td>S</td>
<td>H2\textsuperscript{d}</td>
<td>3,638 ± 436</td>
</tr>
<tr>
<td>CBA/J</td>
<td>R</td>
<td>H2\textsuperscript{k}</td>
<td>8,605 ± 798</td>
</tr>
<tr>
<td>DBA/2</td>
<td>R</td>
<td>H2\textsuperscript{a}</td>
<td>4,770 ± 548</td>
</tr>
<tr>
<td>A/J</td>
<td>R</td>
<td>H2\textsuperscript{a}</td>
<td>6,936 ± 716</td>
</tr>
<tr>
<td>C3H/HePas</td>
<td>R</td>
<td>H2\textsuperscript{k}</td>
<td>33,147 ± 3,140</td>
</tr>
<tr>
<td>Biozi/High</td>
<td>R</td>
<td>Outbred</td>
<td>42,675 ± 4,050</td>
</tr>
<tr>
<td>Biozi/Low</td>
<td>R</td>
<td>Outbred</td>
<td>7,634 ± 852</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Allele of the \textit{Ity} (Nramp) gene conferring resistance (R) or susceptibility (S) to \textit{Salmonella} infection.

\textsuperscript{b} Immunizations were carried out with three doses of 10\textsuperscript{10} CFU (p.o.) or 10\textsuperscript{7} CFU (i.n. or i.p.) on days 0, 21, and 35. Serum samples were collected 1 week after the last immunization dose. Titers were determined in ELISA plates treated with type \textit{d} flagellin (FLA) or group D Salmonella LPS. Values are means of endpoint titers ± SEM of serum pools prepared from each mouse group. Data are based on two independent experiments.
TABLE 3. Immunogenicity of flagellins expressed by different S. enterica serovar Dublin and S. enterica serovar Typhimurium strains, as measured by antiflagellin systemic (IgG) and secreted (IgA) antibody responses elicited in BALB/c mice immunized via the parenteral or mucosal route.

<table>
<thead>
<tr>
<th>Bacterial strain</th>
<th>Immunization route</th>
<th>Serum IgG Antibody titer*</th>
<th>Fecal sIgA</th>
<th>Lung wash sIgA</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. enterica serovar Dublin SL5930</td>
<td>i.p.</td>
<td>24,454 ± 2,689 &lt;2</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Nasal</td>
<td>64 ± 7</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>36 ± 4</td>
<td>&lt;2</td>
<td>15 ± 3</td>
</tr>
<tr>
<td>S. enterica serovar Typhimurium LM408</td>
<td>i.p.</td>
<td>20 ± 3</td>
<td>61,078 ± 7329</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Nasal</td>
<td>30 ± 4</td>
<td>15,409 ± 1694</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>25 ± 2</td>
<td>6,051 ± 617</td>
<td>4 ± 1</td>
</tr>
</tbody>
</table>

* Immunizations were carried out with three doses of 10⁶ CFU (p.o.) or 10⁷ CFU (i.n. or i.p.) on days 0, 21, and 35. Serum, fecal, and lung wash samples were collected 1 week after the last immunization dose. Titers were determined in ELISA plates treated with type flagellin isolated from strain ICB5 (FLA-SD) or with flagellins isolated from strain SL3261 (FLA-ST). Values are means of endpoint titers ± SEM of serum pools prepared from each mouse group. Data are representative of two experiments. ND, not done.

immunized with S. enterica serovar Dublin ICB5 (data not shown). All tested mouse strains developed anti-LPS IgG responses after immunization with strain ICB5 via either the i.p. or p.o. route (Table 2). Such evidence indicates that flagellin immunogenicity can be affected by the genetic composition of the vaccinated mouse strains. Since the C3H/HePas strain expresses the same haplotype (H2b) and Iby' allele as other mouse strains that failed to respond to flagellin, we conclude that type d flagellin immunogenicity following the delivery of attenuated S. enterica serovar Dublin strains via mucosal routes relies on the action of different genetic loci. The polygenic nature of the immune response to Salmonella typhimurium fl flagellin in mice was further demonstrated by similar immunization experiments using outbred Biozzi mouse lines specifically selected for high (H) and low (L) levels of immunological responsiveness to Salmonella antigens (4, 37). The hyporesponsive outbred mouse H strain developed high-level systemic anti-type d flagellin IgG responses (reciprocal titer of 10,613 ± 1,230) after p.o. immunization with the ICB5 strain, while the hyporesponsive L strain developed meager anti-type d flagellin serum IgG responses (reciprocal titer of 56 ± 8) under the same conditions (Table 2). Similar results were found for fecal IgA responses to type d flagellin in the outbred Biozzi mice after oral immunization with the S. enterica serovar Dublin ICB5 vaccine strain (data not shown).

To test the role of the Salmonella vaccine strains on the immunogenicity of flagellin, we immunized unresponsive BALB/c mouse groups via different routes with S. enterica serovar Typhimurium strain LM408, a pLS408-transformed derivative of the aroA S. enterica serovar Typhimurium SL3261 vaccine strain, which simultaneously expresses type d flagellin and type I (type i) and type II (Fiβ) flagellins, encoded by chromosomal genes of the strain. As shown in Table 3, mice immunized via the i.n. or p.o. route with S. enterica serovar Typhimurium LM408 were capable of developing high-level systemic and secreted antibody responses to S. enterica serovar Typhimurium flagellins, but not to the type d flagellin encoded by pLS408. Curiously, antibodies raised in mice immunized with S. enterica serovar Dublin SL5930 did not react with flagellins isolated from the S. enterica serovar Typhimurium SL3261 strain, which shows that, despite their significant amino acid similarities, the different Salmonella flagellin types do not share immunologically dominant B-cell epitopes. Irrespective of that observation, these results show that the immunogenetics of Salmonella flagellins in the murine model are affected by the genetic background of the flagellated vaccine strain delivered via mucosal routes.

Colonization and invasive properties of S. enterica serovar Dublin and S. enterica serovar Typhimurium strains. The distinct immunogenicities of Salmonella flagellins were not ascribed to different colonization and invasion abilities of the bacterial strains. The results presented in Table 4 indicate that the S. enterica serovar Dublin SL5930 strain was recovered from PP and spleens of inoculated BALB/c mice in higher numbers than the S. enterica serovar Typhimurium SL3261 strain after a single oral administration of the bacterial strains. Moreover, S. enterica serovar Dublin SL5930 was detected for up to 45 days in mouse tissues, while under our assay conditions, S. enterica serovar Typhimurium LM408 was detected for up to 3 days in mouse tissues.

<table>
<thead>
<tr>
<th>Bacterial strain</th>
<th>Mouse lineage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Colonization (CFU/5 PP) invasion (CFU/spleen)&lt;sup&gt;b&lt;/sup&gt;</th>
<th>% flagellin expression&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>SL5930 BALB/c</td>
<td>3.5 × 10&lt;sup&gt;10&lt;/sup&gt;/1.1 × 10&lt;sup&gt;2&lt;/sup&gt;</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>C3H/HePas</td>
<td>1.1 × 10&lt;sup&gt;9&lt;/sup&gt;/5.5 × 10&lt;sup&gt;3&lt;/sup&gt;</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>LM408 BALB/c</td>
<td>4.1 × 10&lt;sup&gt;7&lt;/sup&gt;/8 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>C3H/HePas</td>
<td>9.1 × 10&lt;sup&gt;7&lt;/sup&gt;/2.5 × 10&lt;sup&gt;10&lt;/sup&gt;</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> The Salmonella strains were given as a single oral dose (10<sup>10</sup> CFU).
<sup>b</sup> The C3H/HePas and BALB/c mouse strains were chosen for their ability to develop antibody responses to type d flagellin after p.o. immunization with S. enterica serovar Dublin vaccine strains.
<sup>c</sup> Colonization was measured as the number of colonies detected on Luria-novobioin plates inoculated with five homogenized PP collected 7 days after oral inoculation of the animals with one of the tested Salmonella strains. Similarly, invasion was determined after plating of the spleen homogenates of inoculated mice. Numbers represent the total number of bacteria recovered from five PP (colonization) or the whole spleen (invasion) and are the means for three inoculated female mice.
<sup>d</sup> Flagellin expression was measured indirectly by measuring pLS408 stability in the two Salmonella hosts. Colonies recovered from plates inoculated with spleen or PP homogenates were replica plated in ampicillin-containing LB agar plates. Values are percentages of ampicillin-resistant colonies compared to the total number of tested colonies.
Enterica serovar Dublin ICB5 could also promote the activation and C57BL/6 mice (9, 29). To determine whether attenuated enterica agellated (SL5928) or fla/H9253 different administration routes. IFN-HePas mice, which were able to develop anti-type (PP) and invasion (spleen) numbers were obtained with C3H/ a maximum of 21 days (data not shown). Similar colonization (PP) and invasion (spleen) numbers were obtained with C3H/ HePas mice, which were able to develop anti-type d flagellin antibody responses upon oral immunization with flagellated S. enterica serovar Dublin and S. enterica serovar Typhimurium strains (Table 4). Approximately 80% of the colonies recovered from PP and spleens of mice 7 days after inoculation with S. enterica serovar Dublin SL5930 were able to express flagellin, as measured by the presence of pLS408, while <10% of the colonies recovered from mice inoculated with S. enterica serovar Typhimurium LM408 maintained the plasmid (Table 4). Moreover, S. enterica serovar Dublin ICB5, which carries the flIC gene (type d) integrated into the chromosome, does not lose the ability to express flagellin after several passages in mouse tissues (data not shown). Taken together, these results indicate that the reduced B-cell responses to Salmonella flagellins are not due to an impaired ability of the Salmonella strains to infect and/or persist in host tissues. Moreover, the low level of immunogenicity of type d flagellin in the S. enterica serovar Dublin genetic background is not a consequence of the unstable nature of flagellin expression in this bacterial host.

Flagellin-specific cytokine responses elicited in mice orally immunized with S. enterica serovar Dublin vaccine strains. Previous reports have described the activation of flagellin-specific CD4+ T lymphocytes after oral administration of attenuated S. enterica serovar Typhimurium strains to BALB/c and C57BL/6 mice (9, 29). To determine whether attenuated S. enterica serovar Dublin ICB5 could also promote the activation of cell-mediated cytokine responses in vaccinated mice, we measured IFN-γ, IL-10, IL-2, and IL-4 production by spleenocytes isolated from BALB/c mice immunized p.o. or i.p. with S. enterica serovar Dublin ICB5. As shown in Fig. 2, splenocytes isolated from BALB/c mice immunized via parenteral or mucosal routes with the S. enterica serovar Dublin ICB5 strain produced high levels of IFN-γ and IL-10 and moderate amounts of IL-2, but very little IL-4, when stimulated with purified type d flagellin. The amounts of IFN-γ production after flagellin stimulation were similar for the i.p. and p.o. immunized groups, whereas IL-10 levels were twofold higher in splenocyte cultures derived from i.p. immunized mice (Fig. 2). Similar results were observed for cultures treated with polymyxin B, confirming that the cytokine responses to flagellin preparations were not due to residual LPS contamination (data not shown).

When inactivated bacteria were used as an antigenic stimulus, IFN-γ production, but not that of IL-10 or IL-2, was significantly enhanced in splenocyte cultures stimulated with flagellated Salmonella compared to the levels obtained in cultures stimulated with nonflagellated bacteria (Fig. 2). Identical results were observed in assays performed in the presence of polymyxin B to avoid possible splenocyte stimulation by LPS contamination in the flagellin preparations (data not shown). In order to determine the T-lymphocyte population involved in the activation of IFN-γ production as a recall response to flagellin, we treated splenocyte cultures with MAbs that block either CD4+ or CD8-dependent T-cell activation. The addition of an anti-CD4 MAb (GK 1-5) to the splenocyte...
cultures suppressed IFN-γ production about 90%, while an anti-CD8 MAb (TIB105) did not modify the IFN-γ production pattern (Fig. 3A). Regarding IL-10 production, the results depicted in Fig. 3B show that the GK1-5 MAb treatment reduced IL-10 levels about 50%, whereas the TIB105 MAb did not have an effect. Therefore, IFN-γ production in ICB5-immunized mice was primarily CD4-cell-activation dependent, whereas 50% of the IL-10 production was independent of CD4 cell activation. Taken together, these results indicate that, in spite of the reduced antibody responses, mice immunized via the oral route with S. enterica serovar Dublin ICB5 develop strong flagellin-specific CD4-dependent IFN-γ and IL-10 responses.

Salmonella flagellin has been intensively used as a carrier of heterologous B-cell epitopes, either as a purified protein in acellular formulations or as a particular antigen expressed by attenuated vaccine strains. The present results indicate that the production of IFN-γ and IL-10 prevails as the immune response elicited against flagellin in mice orally immunized with S. enterica serovar Dublin strains and suggest that similar immunological responses could be triggered by heterologous T-cell epitopes genetically fused to flagellin. To test this hypothesis, we immunized BALB/c mice with S. enterica serovar Dublin FLA II, which expresses a hybrid flagellin genetically fused to a 15-amino-acid T-cell epitope derived from the structural subunit of the CFA/I fimbriae produced by some ETEC strains (26). As shown in Fig. 4, splenocytes harvested from mice immunized with S. enterica serovar Dublin FLA II delivered i.p. or p.o. produced significant IFN-γ levels in cultures stimulated with purified CFA/I fimbriae. Similar to the results obtained with flagellin, IFN-γ production secondary to in vitro stimulation with CFA/I fimbriae was primarily CD4-cell-activation dependent since the addition of an anti-CD4 MAb almost completely suppressed it, whereas no significant suppression was detected in cultures treated with an anti-CD8 MAb. These results indicate that CD4-cell-activation-dependent IFN-γ production after exposure to flagellin and fused heterologous T-cell epitopes represents a major immune response elicited in

FIG. 3. CD4 cell activation dependence of flagellin-specific IFN-γ and IL-10 production in BALB/c mice immunized with three doses of S. enterica serovar Dublin ICB5 via the oral route. IFN-γ (A) and IL-10 (B) were measured in supernatants from splenocyte cultures stimulated with purified flagellin (25 μg/ml), and an anti-CD4 MAb (GK 1.5), an anti-CD8 MAb (TIB105), or both were added at the beginning of the culture. Controls were splenocyte cultures without an added antibody (medium) and cultures treated with an anti-β-galactosidase MAb (GL 117) (control antibody). Mice were immunized via the p.o. (black bars) or i.p. (gray bars) route. Data from a representative experiment are expressed as means ± SEM of duplicate cultures.
mice immunized via the oral route with flagellated *S. enterica* serovar Dublin vaccine strains.

**DISCUSSION**

Flagellin represents one of the most active bacterial immunogens described thus far, both for innate and adaptive mammalian immune systems (6–8, 12, 13, 17, 18, 21, 46). Reports on the reduced systemic and secreted antibody-inducing properties of *Salmonella* flagellin following mucosal administration of flagellated attenuated *S. enterica* serovar Dublin strains to isogenic mice were thus intriguing (10, 36). In the present report, we have shown that the ability of mice to elicit secreted and systemic antibody responses to flagellin after mucosal administration of attenuated *Salmonella* strains is affected by both host and bacterial factors. Moreover, we showed that, in contrast to the humoral responses elicited by flagellin and heterologous B-cell epitopes genetically fused to it, mice orally immunized with attenuated *S. enterica* serovar Dublin strains expressing a hybrid type *d* flagellin genetically fused with a T-cell epitope derived from the CFA/I fimbriae of ETEC developed a strong induction of CD4-dependent IFN-γ and IL-10 production against both flagellin and the heterologous epitope. Although at the moment we cannot explain the genetic and molecular bases of specific mechanisms involved in the control of B-cell immunogenicity of *Salmonella* flagellin in the murine model, the present work has unveiled so far unnoticed complex host-parasite relationships affecting the development of specific immune responses to flagellin expressed by vaccine strains after the oral administration of live bacterial cells. Therefore, these results have important implications for the understanding of *Salmonella* pathogenicity and the development of vaccines based on flagellin as a carrier protein of heterologous epitopes.

Orally administered vaccines have numerous advantages over parenterally delivered formulations. Nonetheless, the development of a T-cell tolerance state, measured as unresponsiveness to the antigen delivered via parenteral routes in animals previously immunized with the same antigen via the oral route, usually restricts the development of effective mucosal vaccines (43). In fact, recent results indicated that a previous exposure of cultured human monocytes to purified flagellin reduces the activation of the innate immune response to a subsequent exposure to the same antigen due to a stabilization of binding between the flagellin receptor TLR-5 and the interleukin-1 receptor-associated kinase (30). The reduced flagelin-specific antibody responses elicited in mice immunized via mucosal routes with live *Salmonella* strains could therefore reflect continuous exposure to flagellin due to the maintenance of *Salmonella* cells in host tissues favoring the establishment of immunological tolerance. Nonetheless, our experiments showed that oral administration of live *S. enterica* serovar Dublin strains did not reduce the immunogenicity of parenterally delivered flagellin, either as a purified protein or in flagellated *Salmonella* cells, thus indicating that the tolerogenic state was not established in the immunized animals. The recent finding that the *S. enterica* serovar Enteritidis flagellin can induce efficient systemic and secreted antibody responses when incorporated into biodegradable microparticles administered orally to mice further demonstrates that the *Salmonella* flagellin by itself does not lead to oral tolerance (40). Taken together, the available evidence indicates that the low antibody levels induced by orally delivered type *d* flagellin are not due to a tolerogenic state to this protein, but rather may reflect the activation of an immunological response pattern which would favor immune responses other than the production of systemic and secreted antibodies.

The discovery of mucosal adjuvants, such as the cholera or heat-labile toxins, has led to a renewed interest in the development of effective oral vaccines based either on acellular formulations or whole live or inactivated microorganisms (11, 19, 44). In the present work, the incorporation of LT<sub>R192G</sub> as an LT derivative with reduced toxic effects but preserved adjuvant effects, did not enhance type *d* flagellin immunogenicity with regard to the production of systemic and secreted antibody responses in mice immunized via mucosal routes with flagellated *S. enterica* serovar Dublin strains. Such a finding further supports the assumption that low-level antibody responses after flagellin delivery by mucosal routes are not a consequence of low antigen loads or an inefficient activation of mucosa-associated lymphoid tissues but rather reflect an intrinsic characteristic of the immune response by the murine host. These results also emphasize that, in contrast to the case for other antigens, coadministration of a mucosal adjuvant most probably would not overcome the reduced immunogenicity of recombinant flagellins genetically fused to heterologous B epitopes expressed by orally delivered bivalent *S. enterica* serovar Dublin vaccine strains.

Previous evidence indicated that the genetic background of the murine host can modulate the immunological responsiveness to heterologous antigens expressed by parenterally delivered *Salmonella* vaccine strains (15). In an attempt to evaluate...
the role of the genetic composition of the murine host on the immunogenicity of type \( d \) flagellin expressed by attenuated *Salmonella* serovar Dublin strains delivered via mucosal routes, we tested seven mouse strains expressing four different haplotypes and harboring alleles of the \( \text{Ity} \) (Nramp) gene conferring resistance or sensitivity to *Salmonella* infection. Our results confirmed the role of the host genetic background on the immunogenicity of flagellin delivered by attenuated *Salmonella* strains. Our data indicate that the ability to mount secreted and systemic antibody responses to the *Salmonella* type \( d \) flagellin after the oral delivery of attenuated strains is not related to specific H2 mouse haplotypes or the presence of \( \text{Ity} \) alleles, but rather reflects the interplay of genes located outside the H2 complex. An additional piece of evidence of the polygenic nature of antibody responsiveness to *Salmonella* flagellin in the murine model came from experiments using selection III Biozzi mice, which are outbred lines genetically selected for high- and low-level antibody responsiveness to the *Salmonella* flagellar antigen (4, 37). Originally derived from Swiss albino mice, such mouse lines are considered homologous for the relevant alleles involved with the generation of antibody responses, which are considered to comprise 4 to 10 independently segregating loci responsible for the interline differences (35). As expected, high- and low-level responders showed distinct immunological behaviors toward type \( d \) flagellin after the administration of attenuated *Salmonella* serovar Dublin strains via mucosal and parenteral routes. Although the genetic basis of the distinct antibody responsiveness of the two Biozzi strains is still unknown, previous evidence indicates that the T-cell proliferative responses and altered T-helper functions, leading to different types of regulation of T-helper subsets under antigenic stimulation, could be responsible for the interline difference in antibody responsiveness to flagellin (34). These data also stress the importance of a careful interpretation of results based on the use of murine models for the evaluation of vaccine formulations based on attenuated *Salmonella* strains administered via different inoculation routes.

The various *Salmonella* serological flagellin types, although sharing significant amino acid homologies, have specific sequence domains that are able to elicit non-cross-reacting antibodies, which are the basis of the immunological typing of numerous *Salmonella* serovars (22). Indeed, antibodies raised in mice immunized i.p. with type \( d \) or type \( i \) (or FljB) flagellin did not show a significant cross-reaction with each other, further supporting the notion that the immunodominant B-cell epitopes of *Salmonella* flagellins lie at the hypervariable central domain of the protein. The detection of secreted and systemic antiflagellin antibody responses in BALB/c mice orally immunized with a derivative of the *Salmonella* serovar Typhimurium SL3261 strain showed that bacterium-associated factors can also affect flagellin immunogenicity in the mouse model. Attempts to evaluate the role of the bacterial host on the immunogenicity of type \( d \) flagellin were not conclusive due to the unstable behavior of pLS408 in *Salmonella* serovar Typhimurium. However, our results clearly demonstrate that the distinct immunogenicities of type \( d \), type \( i \), and FljB flagellins do not correlate with the colonization and invasive abilities of the *Salmonella* serovars. Further investigations of the differential immunogenicities of the different *Salmonella* flagelin types and the role of the bacterial host on the antibody responses elicited in mice immunized with different vaccine strains are currently under way.

BALB/c mice immunized p.o. with *Salmonella* serovar Dublin strains had enhanced CD4+ cell-activation-dependent IFN-\( \gamma \) and IL-10 production upon stimulation with purified flagellin or flagellated bacterial cells. Previous work demonstrated that flagellin represents a major antigen that stimulates murine CD4+ T-cell clones after p.o. immunization with *Salmonella* serovar Typhimurium SL3261 (9, 29). Flagellin is also known to be an important antigen for the generation of protective responses in mice orally immunized with attenuated *Salmonella* strains (20, 29). Indeed, the induction of IL-2 production has also been detected against a T-cell epitope inserted at the hypervariable region of *Salmonella* flagellin delivered parenterally to mice (42). These results further support the hypothesis that antiflagellin cell-mediated immune responses prevail in most mouse lineages exposed to attenuated *Salmonella* serovar Dublin strains via the intestinal mucosa. The observation that orally delivered *Salmonella* serovar Dublin strains can elicit strong CD4+ cell-activation-dependent IFN-\( \gamma \) responses to type \( d \) flagellin or genetically fused heterologous epitopes suggests that T-cell epitopes derived from antigens of pathogens requiring cell-dependent protective responses would be particularly interesting to test by the *Salmonella*-flagellin bivalent vaccine approach.

Our results showed that the predominant antiflagellin response in BALB/c mice immunized with *Salmonella* serovar Dublin vaccine strains via the p.o. route is the activation of IFN-\( \gamma \) production, which may lead to macrophage activation, and not a B-cell-mediated antibody response. However, an intense antibody response to the T-cell-independent antigen LPS was observed in these vaccinated mice, indicating that the B-cell compartment is also activated by this oral immunization protocol. Further experiments to evaluate the protective immune responses leading to protection against *Salmonella* challenges in the murine model are necessary and will contribute to the elucidation of the mechanisms involved in the protection of animals immunized via the natural port of entry of the pathogen.

During the last three decades, the remarkable immunological properties of bacterial flagellins have contributed to the understanding of different aspects of mammalian innate and adaptive immune systems. Some of the evidence reported in the present work will contribute to the elucidation of new aspects of bacterial flagellins as immune system modulators and will contribute to a more rational use of *Salmonella* flagella as carriers of heterologous epitopes in bivalent vaccine approaches.

**ACKNOWLEDGMENTS**

This work was supported by grants supplied by Fundação de Amparo à Pesquisa do Estado de São Paulo, T. Mosca was part of the undergraduate scientific training program from CNPq and FAPESP. We thankfully acknowledge K. Higuchi, M. N. de Lima, and A. T. Barbosa for technical assistance.

**REFERENCES**

Gasta
Evans, D. G., D. J. Evans, Jr., S. Clegg, and J. A. Pauley.

Eaves-Pyles, T., H. R. Wong, K. Odoms, and R. B. Pyles.

Dickinson, B. L., and J. D. Clements.


Biozzi, G., D. Mouton, O. A. Sant

Salmonella

Almeida, and L. C. S. Ferreira.


Fucose, and characterization of the CFA/I antigen of enterotoxigenic Salmonella.

Strindelius, L., L. D. Wikingsson, and I. Sjo

Siqueira, and J. Couderc.

Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.

Weiner, H. L.


Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robbinson.